High incidence of periprosthetic joint infection with propionibacterium acnes after the use of a stemless shoulder prosthesis with metaphyseal screw fixation - a retrospective cohort study of 241 patients propionibacter infections after eclipse TSA

Abstract Background A stemless shoulder prosthesis with humeral metaphyseal screw fixation was introduced in order to save bone-stock and to facilitate reconstruction of biomechanics (Eclipse®). The aim of this study was to analyze whether the risk of infection is different with this implant compared to conventional shoulder prosthesis. Methods Two hundred and forty-one patients (54.8% females) were operated with a shoulder arthroplasty and followed for median 2.0 (0.1–5.7) years. One hundred and two (42.3%) had received an Eclipse® prosthesis, the remaining patients were operated with other implants. There was an overrepresentation of males in the Eclipse® group (63.7% males) when compared with the control group (31.7% males). Results In the Eclipse® group 10 (9.8%) patients developed a periprosthetic joint infection, as opposed to 1 (0.7%) in the control group. The most common bacteria was Propionibacterium acnes. Unadjusted infection-free survival after 4 years was 88.8% (CI 82.5–95.7) for Eclipse® patients and 95.7% (CI 87.7–100.0) for controls (p = 0.002). After adjustment for age, gender, diagnosis, and type of shoulder prosthesis (total or hemi), the risk ratio for revision due to infection was 4.3 (CI 0.5–39.1) for patients with the Eclipse® prosthesis. Conclusions Deep infections seem to be more common after the use of the metaphyseally fixed Eclipse® prosthesis than after conventional shoulder implants, but a predominance of male gender and younger age in the Eclipse group may have biased our findings. Future studies on larger cohorts and in vitro investigations on bacterial adherence and biofilm formation are needed. Trial registration The study was conducted in accordance with the Helsinki Declaration. The local ethics board (Regionala Etikprövningsnämnden Stockholm) approved the study (Approval number 2015/1590–31, date of issue 2015-10-14). Retrospectively registered